Altium Capital Management LP purchased a new position in Celcuity Inc. (NASDAQ:CELC) during the second quarter, HoldingsChannel reports. The firm purchased 145,000 shares of the company’s stock, valued at approximately $3,480,000.
A number of other institutional investors have also recently made changes to their positions in CELC. BlackRock Inc. lifted its stake in Celcuity by 7.4% during the 1st quarter. BlackRock Inc. now owns 59,243 shares of the company’s stock valued at $850,000 after acquiring an additional 4,075 shares during the period. Gagnon Advisors LLC increased its position in shares of Celcuity by 60.8% during the 1st quarter. Gagnon Advisors LLC now owns 228,035 shares of the company’s stock valued at $3,270,000 after purchasing an additional 86,224 shares during the last quarter. UBS Group AG increased its position in shares of Celcuity by 15.1% during the 1st quarter. UBS Group AG now owns 30,257 shares of the company’s stock valued at $434,000 after purchasing an additional 3,974 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Celcuity by 154.9% during the 1st quarter. Geode Capital Management LLC now owns 48,999 shares of the company’s stock valued at $702,000 after purchasing an additional 29,776 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in shares of Celcuity during the 2nd quarter valued at about $1,965,000. Institutional investors own 42.74% of the company’s stock.
Shares of NASDAQ CELC traded down $0.85 during midday trading on Thursday, reaching $18.01. 1,059 shares of the stock traded hands, compared to its average volume of 86,828. The company has a debt-to-equity ratio of 0.53, a current ratio of 27.51 and a quick ratio of 27.51. The stock has a market capitalization of $268.35 million, a PE ratio of -9.89 and a beta of 1.55. Celcuity Inc. has a one year low of $5.10 and a one year high of $33.01. The company’s 50 day moving average is $20.11 and its 200 day moving average is $22.83.
Several equities research analysts have recently commented on CELC shares. Jefferies Financial Group started coverage on shares of Celcuity in a research report on Tuesday, September 7th. They set a “buy” rating and a $48.00 price target for the company. Canaccord Genuity started coverage on shares of Celcuity in a report on Friday, October 8th. They issued a “buy” rating and a $50.00 target price for the company. Zacks Investment Research raised shares of Celcuity from a “strong sell” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC began coverage on shares of Celcuity in a report on Tuesday, August 10th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Cowen began coverage on shares of Celcuity in a report on Thursday, July 29th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Celcuity presently has an average rating of “Buy” and an average price target of $39.00.
Celcuity, Inc is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that treats it.
Featured Article: Dividend Yield
Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity Inc. (NASDAQ:CELC).
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.